Skip to main content
. Author manuscript; available in PMC: 2024 Mar 27.
Published in final edited form as: Chem Res Toxicol. 2023 Mar 31;36(4):565–569. doi: 10.1021/acs.chemrestox.3c00038

Figure 3.

Figure 3.

CBDQ and vaped CBD juice form adducts with KEAP1 and activate KEAP1-Nrf2 pathway genes. (A) Western blot and (B) densitometry analysis showing adduction of KEAP1 in 16HBEs incubated with synthetic a-CBD or a-CBDQ for 4 h. (C) Streptavidin blot and (D) Western blot for KEAP1 in primary hBECs exposed apically to PG/VG (VC), nonvaped lab-made a-CBD in PG/VG (NV a-CBD), or vaped lab-made a-CBD juice for 20 or 40 5-s puffs using VaPES. Expression of (E) HMOX1 and (F) GPX2 in primary hBECs exposed to nonvaped CBD commercial juice (20 puff equivalent) or 10–20 puffs commercial CBD juice or oil with VaPES. * p < 0.05 vs nonvaped CBD juice unless otherwise noted (ANOVA with Tukey posthoc).